AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00870584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of omalizumab for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
Study NCT00870584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of placebo for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
Study NCT01948856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: J022X ST
Description: Oral administration - During 6 months and according to the approved summary of product characteristics : 1 sachet per day in the morning on an empty stomach~* First month: 4 consecutive days per week during 3 consecutive weeks~* 5 next months: 4 consecutive days per month at monthly intervals
Study NCT01948856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration - During 6 months : 1 sachet per day in the morning on an empty stomach~* First month: 4 consecutive days per week during 3 consecutive weeks~* 5 next months: 4 consecutive days per month at monthly intervals
Study NCT04125953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Andullation
Description: Andullation is a horizontal vibration technique with stochastically modulated vibrations, build-in in a mattress.
Study NCT04125953 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Andullation
Study NCT02559492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
Study NCT02559492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat tablets will be administered orally, twice daily.
Study NCT02559492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB050465
Description: INCB050465 tablets will be administered orally once daily.
Study NCT03131908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2636771
Description: Phase I Starting Dose of GSK2636771: 300 mg by mouth given for 21 days.~Phase II Dose of GSK2636771: Maximum tolerated dose from Phase I.
Study NCT03131908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Phase I and II Dose of Pembrolizumab: 200 mg given by vein every 3 weeks.
Study NCT03103893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: topical formulation
Study NCT04210271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buddy self-testing condition
Study NCT04210271 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control self-screening condition
Study NCT01189383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL15-DC Vaccine
Description: Autologous dendritic cells manufactured with GM-CSF, IL15 and loaded with melanoma/HIV peptides and KLH; then activated with LPS and CD40 Ligand. Approximately 9 x 10\^6 DCs will be injected (subcutaneously)total per vaccination visit. Patients will receive four vaccinations at weeks 0, 4, 8 and 12. At each scheduled vaccination the patient will receive a total of 3 injections, i.e., 3 mL injections at each of 3 anatomical locations.Injection sites are in upper and lower extremities. Subsequent DC injections will be rotated to different locations on the upper and lower extremities.
Study NCT02834949 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Intervention (BMI)
Description: This session includes a discussion related to harm reduction and the student's autonomy to make decisions about the information provided in the session; an alcohol use decisional balance exercise; personalized alcohol-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the student's perception of how much college students drink and actual student norms, (b) a comparison of the student's alcohol consumption vs. norms, (c) an estimate of the student's peak blood alcohol content in the past month, (d) alcohol-related problems experienced, (e) money spent on alcohol, and (f) calories consumed from alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if he or she indicates interest.
Study NCT02834949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention (BMI)
Description: This session includes a discussion related to harm reduction and the student's autonomy to make decisions about the information provided in the session; an alcohol use decisional balance exercise; personalized alcohol-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the student's perception of how much college students drink and actual student norms, (b) a comparison of the student's alcohol consumption vs. norms, (c) an estimate of the student's peak blood alcohol content in the past month, (d) alcohol-related problems experienced, (e) money spent on alcohol, and (f) calories consumed from alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if he or she indicates interest.
Study NCT02834949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Substance-Free Activity Session (SFAS)
Description: The clinician initiates a discussion of the student's college and career goals. Students discuss the values that motivate them as well as how alcohol use may interfere with their ability to accomplish these goals. Students then receive information on graduation rates and income benefits for those who attend and excel in college. They receive personalized feedback on (a) the requirements for their major and intended career, (b) a list of extracurricular activities tailored to their goals, (c) a graph showing time they allocate to their activities, (d) information on stress and depressive symptoms (if applicable) and possible adaptive coping responses and (e) a list of substance-free recreational activities in which they would like to start or continuing engaging.
Study NCT02834949 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Session
Description: The session includes a clinician-led diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (\~30 minutes). At the end of the session, participants will be asked about their reaction to the relaxation techniques and provided with relaxation training handouts.
Study NCT04234737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Description: Hypnotherapy
Study NCT05112796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Class I extractions sites received immediate implants using the Vestibular Socket Therapy
Description: A 1-cm-long vestibular access incision was made using a 15c blade 3 to 4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision
Study NCT05112796 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: class I extractions sites received immediate implants using the Partial Extraction Therapy
Description: the hopeless tooth was decoronated 1 mm coronal to the gingival margin using a diamond bur. Then, the facial root segment was separated from the rest of the root using a Lindemann bur in gentle mesiodistal sweeping strokes from the gingival margin to the apex of the root, aiming to separate the palatal and the labial root segments.
Study NCT03012581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Treatment
Study NCT03601637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM
Description: Fixed Dose Combination (FDC) granules (LUM/IVA).
Study NCT03601637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: FDC granules (LUM/IVA).
Study NCT03675828 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Visit
Description: The Cleveland Clinic Express Care Online application will be used in this intervention. The subjects will have a virtual consult with a clinician from the study team that will mirror an experience had at an outpatient post-discharge visit, including review of systems and medications.
Study NCT01353469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin human/Insuman Comb 25 (HR1799)
Description: Pharmaceutical form:Suspension~Route of administration: Subcutaneous
Study NCT01353469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin human/Novolin® 30R
Description: Pharmaceutical form:Suspension~Route of administration: Subcutaneous
Study NCT04452656 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral erector spinae block
Description: An ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process.~Three muscles; trapezius , rhomboids major , and erector spinae will be identified superior to the hyperechoic transverse process.~Using in-plane approach a 25 G needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle.~Correct needle tip location will be confirmed by injecting 3 mL of saline and visualizing the linear LA spread in the fascial plane between the erector spinae muscle and the transverse process..~0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) will be injected and visualizing the linear LA spread in the fascial plane between the erector spinae muscle andthe transverse process12.
Study NCT02332148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3VM1001
Description: 3VM1001 topical cream for treatment of osteoarthritis of the knee
Study NCT02332148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for 3VM1001
Description: Topical cream placebo for 3VM1001; cream without 3VM1001
Study NCT03962023 — intervention group
Intervention type: OTHER
Intervention: Echocardiography and MRI
Description: Analysis of echocardiography and MRI parameters
Study NCT02916290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuzhenghuayu
Study NCT01800942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin and Placebo
Description: A single oral dose of 2g of Azithromycin will be given to the women in labour
Study NCT01800942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin and Placebo
Description: A single oral dose of 2g of Azithromycin will be given to the women in labour
Study NCT03257189 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Physiological signal monitor
Description: Wireless remote monitoring system intended for use by researchers and healthcare professionals for continuous collection of physiological data in home and healthcare settings.
Study NCT03257189 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Heart rate and heart rate variability comparison device
Description: FDA cleared reference device that monitors heart rate and heart rate variability in subjects
Study NCT03257189 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Respiration rate comparison device
Description: FDA cleared reference device that monitors respiration rate in subjects
Study NCT03257189 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Activity classification
Description: Visual annotation of subject posture and other activities used for reference
Study NCT01907386 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: QSE-LSME - SSWI Ultrasound
Description: Doppler ultrasound (DUS) and elastographic examinations will be performed using a single probe (6-1 MHz, Super Curved, Vermon, Tours, France) with the clinical Aixplorer system (Supersonic Imagine, Aix-en-Provence, France), a new generation ultrasound scanner providing an outstanding B-mode and color-Doppler image quality, allowing exportation of RF images for QSE-LSME acquisition and integrating the shear wave elastography (SSWI) mode.
Study NCT02312973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat(BAY85-3934)
Description: Two single oral doses of 75 mg molidustat tablet in subjects on hemodialysis and peritoneal dialysis
Study NCT03291093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Flutemetamol PET/MRI
Description: All patients will undergo a PET/MRI of the carotids after 18F-Flutemetamol injection.
Study NCT02889029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new 3D device
Description: dedicated tailored stents wrought by 3D computer-assisted conception
Study NCT04267224 — intervention group
Intervention type: DRUG
Intervention: Ticagrelor 90mg
Description: Ticagrelor is a direct-acting inhibitor of the platelet P2Y12 receptor with a rapid antiplatelet effect. It has been shown to reduce the rate of major cardiovascular events among patients with acute coronary syndromes, as compared with Clopidogrel, and has the potential to improve coronary reperfusion and the prognosis for patients with STEMI treated with primary PCI.
Study NCT00363545 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilized formulation of HRV vaccine
Description: Lyophilized formulation of HRV vaccine
Study NCT00363545 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liquid formulation of HRV vaccine
Description: Liquid formulation of HRV vaccine
Study NCT01158001 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged exposure therapy
Description: Twelve sessions (90 minutes each) of prolonged exposure therapy
Study NCT01158001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Description: Twelve sessions (90 minutes each) of prolonged exposure therapy
Study NCT01588470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: 45 mg per day for 6 months
Study NCT04583059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taping
Description: A hard-preventive Zinc oxide tape was used in this study. Taping procedure consists of three separate steps: First step involved application of the anchor tape, which achieved by applying the tape circumferentially just above the malleolar level at the lo
Study NCT03417713 — intervention group
Intervention type: DEVICE
Intervention: Fluoroscopic imaging with the OEC Elite Device
Description: Vascular, gastrointestinal (GI), urology or pain management procedures for which use of the OEC Elite system in the vascular configuration would be prescribed.
Study NCT04580641 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: A self-administered questionnaire will be completed by each study subject
Study NCT04501692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VivaSight
Description: see above
Study NCT04501692 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Videolaryngoscopy
Description: see above
Study NCT02916290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA
Study NCT03900325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimacimab
Description: 2.5 mg/kg
Study NCT03900325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride
Study NCT02941172 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cold exposure
Description: Controlled cold exposure is performed before and during PET scan
Study NCT02941172 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: [18F]FMPEP-d2
Description: PET radiotracer used in imaging
Study NCT02941172 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: [18F]FDG
Description: PET radiotracer used in imaging
Study NCT04017195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVRA patch (NGMN+EE) (Treatment A) (Reference)
Description: A single transdermal contraceptive patch of EVRA (NGMN + EE) will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.
Study NCT02916290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UDCA
Study NCT03463369 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-64300535
Description: Participants will receive JNJ-64300535 vaccine by electroporation-mediated IM injection on Day 1, Week 4, and Week 12.
Study NCT03463369 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive 1 mL (0.9 percent \[%\] sodium chloride \[NaCl\]) of placebo solution matching to JNJ-64300535 electroporation-mediated IM injection on Day 1, Week 4, and Week 12.
Study NCT03463369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide Analogs (NA)
Description: Participants will receive NA as a standard of care treatment.
Study NCT01029470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luveris
Description: Luveris 75IU or 150IU depending on the patient conditions, subcutaneous injection, Qd, from Day 8 till hCG Day
Study NCT03764709 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vital signs wireless monitoring system
Description: WIN@Hospital wireless remote monitoring is a modern light monitoring medical device with no need for continuous presence of a dedicated person. WIN@Hospital is based on an innovative modular and wearable device laid out for remote monitoring of several vital parameters 24/7. Dexcom G6 is a continuous glucose monitoring system which measures interstitial fluid glucose levels in people with diabetes from a sensor applied to the skin as an alternative to routine finger-prick blood glucose testing, and can produce a -continuous record of measurements which can be checked using an App. It can also indicate glucose level trends over time. Monitoring devices will be applied to all patients randomly assigned to the wireless monitoring arm, with a continuous monitoring setting over the first 5 days after the initiation of monitoring, corresponding to the starting of the observation (i.e. transition to subacute unit for GROUP A, discharge for GROUP B).
Study NCT03764709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vital signs wireless monitoring system
Description: WIN@Hospital wireless remote monitoring is a modern light monitoring medical device with no need for continuous presence of a dedicated person. WIN@Hospital is based on an innovative modular and wearable device laid out for remote monitoring of several vital parameters 24/7. Dexcom G6 is a continuous glucose monitoring system which measures interstitial fluid glucose levels in people with diabetes from a sensor applied to the skin as an alternative to routine finger-prick blood glucose testing, and can produce a -continuous record of measurements which can be checked using an App. It can also indicate glucose level trends over time. Monitoring devices will be applied to all patients randomly assigned to the wireless monitoring arm, with a continuous monitoring setting over the first 5 days after the initiation of monitoring, corresponding to the starting of the observation (i.e. transition to subacute unit for GROUP A, discharge for GROUP B).
Study NCT03375684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
Study NCT02312973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat(BAY85-3934)
Description: One single oral dose of 75 mg molidustat in healthy subjects
Study NCT00136812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stage-tailored intervention
Description: This intervention consists of nicotine patch therapy during hospitalization; a stage-based self-help manual; an individualized, expert-system, feedback report at intake, 3 months and 6 months post-hospitalization with carbon copies sent to participants' outpatient clinicians; and an individual 30-min smoking cessation counseling sessions during hospitalization. Additionally, up to 10 weeks of nicotine patch is provided to intervention participants intending to stay quit following hospital discharge.
Study NCT02999620 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-cyclodextrin
Description: Alpha-cyclodextrin (α-CD) is a soluble dietary fiber that has a history of use in foods and as a pharmaceutical excipient. Recently the ability of the fiber to bind to dietary fat has led to further investigation of the possible health benefits of dietary supplementation with this fiber.
Study NCT02999620 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical looking placebo tablet to active (Alpha-cyclodextrin)
Study NCT02738671 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive assessment
Study NCT03474055 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liquid Rotavirus Vaccine
Description: Liquid Rotavirus Vaccine and Lyophilized Rotavirus Vaccine
Study NCT03474055 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Liquid Rotavirus Vaccine
Description: Liquid Rotavirus Vaccine and Lyophilized Rotavirus Vaccine
Study NCT03885778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifovir dipivoxil
Description: 150mg Besifovir dipivoxil, single dose, oral
Study NCT02502864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care: Docetaxel
Description: Pharmacokinetic(PK)-guided docetaxel. Cycle 1: 75 mg/m\^2, intravenously (IV) on Day 1 for 60 minutes. Beginning with cycle 2, the docetaxel dose will be individually adjusted before each cycle.